Short Reads

Recent European Commission merger decisions signal an increased focus on innovation

Recent European Commission merger decisions signal an increased focus

Recent European Commission merger decisions signal an increased focus on innovation

03.07.2017

On 27 March 2017, the European Commission approved a merger between chemical companies Dow and DuPont subject to major remedies, including the divestment of DuPont's global R&D organisation. In this case, the Commission's review extended to the merger's potential impact on innovation "at the overall industry level". 

The Commission considered that innovation is a key competitive parameter in the pesticides industry. According to the Commission, post-merger, only three integrated players could effectively compete with Dow/DuPont at a global level throughout the entire (R&D) value chain (from discovering new active ingredients, to the manufacture and sale of final products). The Commission relied on evidence showing that the parties intended to cut back on R&D expenditure, and that the merged entity would have less incentives to innovate than Dow and DuPont would have separately. As a result, the Commission found that the merger would have significantly reduced "innovation competition" for pesticides, and called for the divestment of the vast majority of DuPont's global R&D organisation.

The importance of "innovation" as an assessment parameter under EU merger control law is not particularly new and is reflected in the Commission's horizontal merger guidelines (the Guidelines). The Guidelines, for example, recognise that a merger between two important innovators developing competing "pipeline" products (in a specific product market) may, under certain conditions, impede competition.

The assessment of such "pipeline overlaps" has played a role in numerous pharmaceutical merger decisions over the years. Traditionally, the Commission focused its review on pipeline products that have entered late phase (phase III) clinical trials. Such products have a higher likelihood of entering the market within a reasonably foreseeable timeframe. In recent years, however, the Commission has extended its review to products in the early stages of development, many of which may never be marketed. In Novartis/GSK Oncology, for example, the Commission analysed the merger's potential impact on the parties' overall clinical research programmes for ovarian and skin cancer treatments, including very early phase (phase I) pipeline products. More recently, on 9 June 2017, the Commission cleared a merger between J&J and Actelion, subject to commitments ensuring that the parties' phase II pipeline products would not be delayed or discontinued.

These developments show that – at least in innovation intensive industries – the Commission will continue to review the merging parties' full R&D portfolios in detail. This may require significant additional preparatory work (e.g. in terms of document collection and preparing economic analyses) before mergers are filed.

This article was published in the Competition Law Newsletter of July 2017. Other articles in this newsletter:

  1. Google gets a record EUR 2.42 billion antitrust fine for its shopping service
  2. ACM fines Dutch rail operator (NS) for an alleged abuse of dominance
  3. New Belgian Act on damage claims for competition law infringements

Team

Related news

03.06.2022 NL law
Podcast: circulair ondernemen en de juridische mogelijkheden en beperkingen

Short Reads - In deze Stibbe Legal Insights gaan Bram Schmidt, Ida Mae de Waal en Christian van Maaren in op het juridisch kader bij circulariteit. Zij bespreken de transitie naar een circulaire economie en hoe bedrijven, ondanks de beperkingen van huidige wet- en regelgeving, meer circulair kunnen opereren. Ook bespreken zij hoe bedrijven zich kunnen voorbereiden op nieuwe Europese wet- en regelgeving op het gebied van hergebruik, recyclen en circulair productontwerp.

Read more

01.06.2022 NL law
AG Emiliou: careful treading in hybrid cartel procedures

Short Reads - On 12 May 2022, Advocate General (AG) Emiliou delivered his Opinion proposing that the European Court of Justice (ECJ) dismiss HSBC’s appeal. Although the AG criticised the General Court’s analysis of the procedural aspects and its understanding of the ‘by object’ case law, he found that, were the grounds of the General Court’s judgment to be substituted, the operative part of the judgment could be considered well founded based on the adjusted legal grounds. Therefore, the General Court’s errors have not affected the outcome of the proceedings against HSBC.

Read more

01.06.2022 NL law
The new VBER is here! Time to update your distribution agreements

Short Reads - The new Vertical Block Exemption Regulation (VBER) entered into force on 1 June 2022. The new VBER is stricter on dual distribution and across-platform retail parity obligations than the old one, but is more lenient towards active sales and online sales restrictions. It also provides more guidance on the rules for exclusive and selective distribution systems.

Read more

01.06.2022 EU law
Park your parking structures: EU Court upholds Canon’s gun jumping fine

Short Reads - Companies involved in M&A transactions had better think twice before temporarily parking a target undertaking with an interim buyer. On 18 May 2022, the General Court upheld the European Commission's EUR 28 million gun jumping fine imposed on Canon for partially implementing its two-step takeover of Toshiba Medical Systems Corporation (TMSC) prior to notification and clearance.

Read more